Meitheal Reveals Manufacturing Expansion Plans
Increasing Capacity To Produce Heparin Amid Supply Concerns
Meithal Pharmaceuticals has revealed future plans to expand its manufacturing capabilities as the US FDA approved a new vial manufacturing line that will double the firm’s capacity to supply the US market.
You may also be interested in...
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
Launching eight heparin vial presentations in the US is evidence of how injectables specialist Meitheal Pharmaceuticals intends to leverage the vertically-integrated production capacity of its Chinese parent group NKF.
China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.